Chronic myelogenous leukemia: Molecular and cellular aspects

Journal of Cancer Research and Clinical Oncology

Volumn 124, Issue 12, 1998, Pages 643-660

  Pasternak, Günter ^a   Hochhaus, Andreas ^a   Schultheis, Beate ^a   Hehlmann, Rüdiger ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Adhesion molecules; BCR ABL fusion gene; BCR ABL tyrosine kinase; Chronic myelogenous leukemia; CML long term culture; Philadelphia chromosome

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; CHROMOSOME 9; CHRONIC MYELOID LEUKEMIA; GRANULOCYTE; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REVIEW;

ANIMALS; BLAST CRISIS; CHROMOSOME ABERRATIONS; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; OLIGONUCLEOTIDES, ANTISENSE; PHILADELPHIA CHROMOSOME; STROMAL CELLS;

EID: 0032410635     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320050228     Document Type: Review

References (167)

1. Abelson HT, Rabstein LS (1970) Lymphosarcoma: virus-induced thymic-independent disease in mice. Cancer Res 30:2213-2222
2. Afar DEH, Goga A, McLaughlin J, Witte ON, Sawyers CL (1994) Differential complementation of BCR-ABL point mutants with c-MYC. Science 264:424-426
3. Ahuja H, Bar-Eli M, Advani SH, Benchimol S, Cline MJ (1989) Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proc Natl Acad Sci USA 86:6783 6787
4. Barnett MJ, Eaves CJ, Phillips GL, Kalousek DK, Klingemann H-G, Lansdorp PM, Reece DE, Shepherd GJ, Shaw GJ, Eaves AC (1989) Successful autografting in chronic myeloid leukaemia after maintenance of marrow in culture. Bone Marrow Transplant 4:345-351
5. Barnett MJ, Eaves CJ, Phillips GL, Gascoyne RD, Hogge DE, Horsman DE, Humphries RK, Klingemann H-G, Lansdorp PM, Nantel SH, Reece DE, Shepherd JD, Spinelli JJ, Sutherland HJ, Eaves AC (1994) Autografting with cultured marrow in chronic myeloid leukemia: results of a pilot study. Blood 84:724-732
6. Barrett AJ, Malkovska V (1996) Graft-versus-leukaemia: understanding and using the alloimmune response to treat haematological malignancies. Br J Haematol 93:754-761
7. Bartram CR, de Klein A, Hagemeijer A, Agthoven T van, Geurts van Kessel A, Bootsma D, Grosveld G, Ferguson-Smith MA, Davies T, Stone M, Heisterkamp N, Stephenson JR, Groffen J (1983) Translocation of the c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukemia. Nature 306:277-280
8. Bartram CR, Janssen JWG, Becher R, Klein A de, Grosveld G (1986) Persistence of chronic myelocytic leukemia despite deletion of rearranged bcr/c-abl sequences in blast crisis. J Exp Med 164:1389-1396
9. Bazzoni G, Carlesso N, Griffin JD, Hemler ME (1996) BCR/ABL expression stimulates integrin function in hematopoietic cell lines. J Clin Invest 98:521-528
10. Bhatia R, Verfaillie CM (1998) Inhibition of BCR-ABL expression with antisense oligonucleotides restores β1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors. Blood 91:3414-3422
11. Bhatia, R, Wayner EA, McGlave PB, Verfaillie CM (1994) Interferon-α restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired β1 integrin receptor function. J Clin Invest 94:384-391
12. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P (1995) Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 86:3118-3122
13. Bocchia M, Wentworth PA, Southwood S, Sidney J, McGraw K, Scheinberg DA, Sette A (1995) Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 85:2680-2684
14. Bocchia M, Korontsvit T, Xu Q, Mackinnon St, Yang SY, Sette A, Scheinberg DA (1996) Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 87:3587-3592
15. + T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood 88:3522-3527
16. Brandt L, Mitelman F, Panani A, Lenner HC (1976) Extremely long duration of chronic myeloid leukaemia with Ph' negative and Ph' positive bone marrow cells. Scand J Haematol 16:321-325
17. Brito-Bapapulle B, Bowcock SJ, Marcus RE, Apperley J, Th'ng KH, Dowding C, Rassool F, Guo AP, Catovsky D, Galton DAG, McCarthy D, Goldman JM (1989) Autografting for patients with chronic myeloid leukemia in chronic phase: peripheral blood stem cells may have a finite capacity for maintaining haemopoiesis. Br J Haematol 73:76-81
18. Burnett AK, Watkins R, Maharaj D, McKinnon S, Tansey P, Alcorn M, Singer CRJ, McDonald GA, Robertson AG (1984) Transplantation of unpurged autologous bone marrow in acute myeloid leukaemia in first remission. Lancet 2:1068-1070
19. Butturini A, Keating A, Goldman J, Gale RP (1990) Autotransplants in chronic myelogenous leukaemia: strategies and results. Lancet 335:1255-1258
20. Carlo-Stella C, Dotti G, Mangoni L, Regazzi E, Garau D, Bonati A, Almici C, Sammarelli G, Savoldo B, Rizzo MT, Rizzoli V (1996) Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein. Blood 88:3091-3100
21. Caspersson T, Gahrton G, Lindsten J, Zech A (1970) Identification of the Philadelphia chromosome as a number 22 by quinacrine mustard fluorescence analysis. Exp Cell Res 63:238-240
22. Cervantes F, Rozman C (1994) Benign hematopoietic progenitors in chronic myeloid leukemia: current status and future prospects. Ann Hematol 69:99-105
23. Cervantes F, Pierson BA, McGlave PB, Verfaillie CM, Miller JS (1996) Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture. Blood 87:2476-2485
24. Chang J, Allen TD, Dexter TM (1989) Long-term bone marrow cultures: their use in autologous marrow transplantation. Cancer Cells 1:17-24
25. Chen W, Peace DJ, Rovira DK, You S-G, Cheever MA (1992) T-cell immunity to the joining region of p210BCR-ABL protein. Proc Natl Acad Sci USA 89:1468-1472
26. Chervenick PA, Ellis LD, Pan SF, Lawson AL (1971) Human leukemic cells: in vitro growth of colonies containing the Philadelphia chromosome. Science 174:1134-1136
27. Chissoe SL, Bodenteich A, Wang YF, Wang YP, Burian D, Clifton SW, Crabtree J, Freeman A, Iyer K, Jian L, Ma Y, McLaury HJ, Pan HQ, Sarhan OH, Toth S, Wang Z, Zhang G, Heisterkamp N, Groffen J, Roe BA (1995) Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation. Genomics 27:67-82
28. Clark SS, Crist WM, Witte ON (1989) Molecular pathogenesis of Ph-positive leukemias. Annu Rev Med 40:113-122
29. Clarkson BD, Strife A (1991) Discordant maturation in chronic myelogenous leukemia. In: Deisseroth AB, Arlinghaus RB (eds) Chronic myelogenous leukemia. M. Dekker, New York, pp 3-72
30. Clarkson BD, Strife A, Wisniewski D, Lambek C, Carpino N (1997) New understanding of the pathogenesis of CML: a prototype of early neoplasia. Leukemia 11:1404-1428
31. Trialists' Collaborative Group (1997) Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Nat Cancer Inst USA 89:1616-1620
32. Coleman S, Fisher J, Hoy T, Burnett AK, Lim SH (1996) Autologous MHC-dependent leukaemia-reactive T lymphocytes in a patient with chronic myeloid leukaemia. Leukemia 10:483-487
33. Collins SJ (1986) Breakpoints on chromosomes 9 and 22 in Philadelphia chromosome positive CML: amplification of rearranged c-abl oncogenes in CML blast crisis. J Clin Invest 78:1392-1396
34. Collins SJ (1991) bcr-abl structure and expression in chronic myelogenous leukemia chronic phase and blast phase. In: Deisseroth AB, Arlinghaus RB (eds) Chronic myelogenous leukemia. Dekker, New York, pp 3-72
35. Cotter TG (1995) BCR/ABL: an anti-apoptosis gene in chronic myelogenous leukemia. Leukemia lymphoma 18:231-236
36. Coulombel L, Kalousek DK, Eaves CJ, Gupta CM, Eaves AC (1983) Long-term bone marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Ph' chromosome-positive chronic myeloid leukemia. N Engl J Med 308:1493-1498
37. Daley GQ, Baltimore D (1988) Transformation of an interleukin-3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific p210 bcr/abl protein. Proc Natl Acad Sci USA 85:9312-9316
38. Daley GQ, Etten RA van, Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by p210bcr/abl gene of the Philadelphia chromosome. Science 247:824-830
39. Denderen J van, Hermans A, Meeuwsen T, Troelstra C, Zegers N, Boersma W, Grosveld G, van Ewijk W (1989) Antibody recognition of the tumor-specific bcr-abl joining region in chronic myeloid leukemia. J Exp Med 169:87-98
40. Deininger MW, Goldman JM, Lydon N, Melo JV (1997) The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90:3691-3698
41. Dexter TM; Coutinho LH, Spooncer E, Heyworth CM, Daniel CP, Schiro R, Chang J, Allen TD (1990) Stromal cells in haemopoiesis. Ciba Found Symp 148:76-86
42. Diamond J, Goldman JM, Melo JV (1995) BCR-ABL, ABL-BCR, BCR, and ABL genes are all expressed in individual granulocyte-macrophage colony-forming unit colonies derived from blood of patients with chronic myeloid leukemia. Blood 85:2171-2175
43. rac. Nature 351:400-402
44. Dowding C, Guo AP, Osterholz J, Siczkowski M, Goldman J, Gordon M (1991) Interferon-α overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cell. Blood 78:499-505
45. Druker B, Okuda K, Matulonis U, Salgia R, Roberts T, Griffin JD (1992) Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines. Blood 79:2215-2220
46. Druker B, Buchdunger E, Ohno-Jones S, Lydon NB (1997) Preclinical evaluation of an inhibitor of the ABL tyrosine kinase as a therapeutic agent for chronic myelogenous leukemia (abstract). J Mol Med 75:B222
47. Dubé ID, Kalousek DK, Coulombel L, Gupta CM, Eaves CJ, Eaves AC (1984) Cytogenetic studies of early myeloid progenitor compartments in Ph' positive myeloid leukemia (CML). II. Long-term culture reveals the persistence of Ph' negative progenitors in treated as well as newly diagnosed patients. Blood 63:1172-1177
48. Dunbar CE, Stewart FM (1992) Separating the wheat from the chaff: selection of benign hematopoietic cells in chronic myeloid leukemia. Blood 79:1107-1110
49. Eaves C, Udomsakdi C, Cashman J, Barnett M, Eaves A (1993) The biology of normal and neoplastic stem cells in CML. Leukemia Lymphoma 11 [Suppl 1]:245-253
50. Elefanty AG, Cory S (1992) Hematologic disease induced in BALB c mice by a BCR/ABL retrovirus is influenced by the infection conditions. Mol Cell Biol 12:1755-1763
51. Elefanty AG, Hariharan IK, Cory S (1990) BCR ABL, the hall mark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J 9:1069-1078
52. Ernst TJ, Slattery KE, Griffin JD (1994) p210Bcr Abl and p160v-Abl induce an increase in the tyrosine phosphorylation of p93c-Fes. J Biol Chem 269:5764-5769
53. Eva A, Aaronson SA (1985) Isolation of a new human oncongene from a diffuse B-cell lymphoma. Nature 316:273-275
54. Fabritiis P de, Amadori S, Calabretta B, Mandelli F (1993) Elimination of clonogenic Philadelphia positive cells using BCR-ABL antisense oligodeoxynucleotides. Bone Marrow Transpl 12:261-265
55. Fabritiis P de, Amadori S, Petti MC, Mancini M, Montefusco E, Picardi A, Geiser T, Campbell K, Calabretta B, Mandelli F (1995) In vitro purging with BCR-ABL antisense oligodeoxynucleotides does not prevent haematologic reconstitution after autologous bone marrow transplantation. Leukemia 9:662-664
56. Fabritiis P de, Skorski T, Propris MS de, Paggi MG, Nieborowska-Skorska M, Lisci A, Buffolino S, Campbell K, Geiser T, Calabretta B (1997) Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukaemia cells. Leukemia 11:811-819
57. Fabritiis P de, Petti MC, Montefusco E, Propris MS de, Sala R, Bellucci R, Mancini M, Lisci A, Bonetto F, Geiser T, Calabretta B, Mandelli F (1998) BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase. Blood 91:3156-3162
58. Fialkow PJ, Jacobson MB, Papayannopoulou T (1997) Chronic myelocytic leukemia: clonal origin in a stem cell common to granulocyte, erythrocyte, platelet and monocyte macrophage. Am J Med 63:125-130
59. Gewirtz AM (1994) Treatment of chronic myelogenous leukemia (CML) with c-myb antisense oligonucleotides. Bone Marrow Transpl 14 [Suppl 3]:57-61
60. Gishizky ML (1997) Identification of therapeutic targets in BCR ABL signal transduction pathways (abstract). J Mol Med 75:B 221
61. Goga A, McLaughlin J, Afar DEH, Saffran DC, Witte ON (1995) Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell 82:981-988
62. Gordon MY, Dowding C, Riley G, Goldman JM, Greaves M (1987) Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 328:342-344
63. Gordon MY, Goldman JM (1996) Cellular and molecular mechanisms in chronic myeloid leukemia. Br J Haematol 95:10-20
64. Groffen J, Stephenson JR, Heisterkamp N, Klein A de, Bartram CR, Grosveld G (1984) Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22, Cell 36:93-99
65. Groffen J, Morris C, Heisterkamp N (1991) Philadelphia chromosome translocation. In: Deisseroth AB, Arlinghaus RB (eds) Chronic myelogenous leukemia. Dekker, New York, pp 181-209
66. Groffen J, Voncken W, Jong R de, Kaartinen V, Heisterkamp N (1997) BCR function and implication to BCR ABL caused leukemias (abstract). J Mol Med 75:B150
67. Guo JQ, Lian JY, Xian YM, Lee M-S, Deisseroth AB, Stass SA, Champlin RE, Talpas M, Wang JYJ, Arlinghaus RB (1994) BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy. Blood 83:3629-3637
68. Haferlach T, Winkemann M, Nickenig C, Meeder M, Ramm-Petersen L, Schoch R, Nickelsen M, Weber-Matthiesen K, Schlegelberger B, Schoch C, Gassmann W, Löffler H (1997) Which compartments are involved in Philadelphia-chromosome positive chronic myeloid leukemia? An answer at the single cell level by combining May-Grünwald-Giemsa staining and in situ hybridization techniques. Br J Haematol 97:99-106
69. 1 chromosome and development of new clonal subpopulations. Blood 53:1-14
70. Hao Q-L, Thiemann FT, Petersen D, Smogorzewska EM, Crooks GM (1996) Extended long-term culture reveals a highly quiescent and primitive human hematopoietic progenitor population. Blood 88:3306-3313
71. Hart MJ, Eva A, Evans T, Aaronson SA, Cerione RA (1991) Catalysis of guanine nucleotide exchange on the CDC42Hs protein by the dbl oncogene product. Nature 354:311-314
72. Hayata I, Sakurai M, Kakati S, Sandberg A (1975) Chromosomes and causation of human cancer and leukemia. XVI. Banding studies of chronic myelocytic leukemia, including five unsual Ph' translocations. Cancer 36:1177-1191
73. Heaney C, Kolibaba K, Bhat A, Oda T, Ohno S, Fanning S, Druker BJ (1997) Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation. Blood 89:297-306
74. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queißer W. Löffler H, Heinze B, Georgii A, Wussow P von, Bartram CR, Grießhammer M, Bergmann L, Essers U, Falge C, Hochhaus A, Queißer U, Sick C, Meyer P, Schmitz N, Verpoort K, Eimermacher H, Walther F, Westerhausen M, Kleeberg UR, Heilein A, Käbisch A, Barz C, Zimmermann R, Meuret G, Tichelli A, Berdel WE, Kanz L, Anger B, Tigges FJ, Schmid L, Brockhaus W, Zankovich R, Schläfer U, Weißenfels I, Mainzer K, Tobler A, Perker M, Hohnloser J, Messerer D, Thiele J, Buhr T, Ansari H, German CML Study Group (1993) Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia (CML): prolongation of survival by hydroxyurea. Blood 82:398-407
75. Hehlmann H, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queißer W, Löffler H, Hochhaus A, Heinze B, Georgii A, Bartram CR, Grießhammer M, Bergmann L, Essers U, Falge C, Queißer U, Meyer P, Schmitz N, Eimermacher H, Walther F, Fett W, Kleeberg UR, Käbisch A, Nerl C, Zimmermann R, Meuret G, Tichelli A, Kanz L, Tigges FJ, Schmid L, Brockhaus W, Tobler A, Reiler A, Perker M, Emmerich B, Verpoort K, Zankovich R, Wussow P von, Prümmer O, Thiele J, Buhr T, Ansari H, German CMI, Study Group (1994) Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 84:4064-4077
76. Hehlmann R, Ansari H, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, Löffler H, Pralle H, Queisser W, Reiter A, Hochhaus A, German CML Study Group (1997) Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. Br J Haematol 97:76-85
77. Heissig B, Schultheis B, Hochhaus A, Pasternak G, Hehlmann R (1997) A significant proportion of bcr-abl positive hematopoietic progenitors is present after long-term culture of peripheral blood mononuclear cells from CML patients on interferon-α therapy (abstract). J Mol Med 75:B247
78. Heisterkamp N, Stephenson JR, Groffen J, Hansen PF, Klein A de, Bartram CR, Grosveld G (1983) Localization of the c-abl oncogene adjacent to a translocation breakpoint in chronic myelocytic leukemia. Nature 306:239-242
79. Heisterkamp N, Groffen J, Stephenson JR (1985a) The human v-abl cellular homologue. J Mol Appl Genet 2:57-68
80. 1 translocation. Nature 315:758-761
81. Heisterkamp N, Jenster G, Hoeve J ten, Zovich D, Pattengale PK, Groffen J (1990) Acute leukaemia in bcr abl transgenic mice. Nature 344:251-253
82. Heisterkamp N, Jong R de, Groffen J (1997) Altered signalling in BCR ABL caused leukemias (abstract). J Mol Med 75:B249
83. Hochhaus A, Reiter A, Skladny H, Melo JV, Sick C, Berger U, Guo JQ, Arlinghaus RB, Hehlmann R, Goldman JM, Cross NCP (1996) A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia. Blood 88:2236-2240
84. Hoeve J ten, Arlinghaus RB, Guo JQ, Heisterkamp N, Groffen J (1994) Tyrosine phosphorylation of CRKL in Philadelphia leukemia. Blood 84:1731-1736
85. 1 positive leukemias. Blood 91:2067-2075
86. Hurley R, McCarthy JB, Verfaillie CM (1995) Direct adhesion to bone marrow stroma via fibronectin receptors inhibits hematopoietic progenitor proliferation. J Clin Invest 96:511-519
87. ISCN (1985) An international system for human cytogenetic nomenclature. Harnden DG, Klinger HP (eds). Published in collaboration with Cytogenet Cell Genet. Karger, Basel
88. Jong R de, Hoeve J ten, Heisterkamp N, Groffen J (1995) Crkl is complexed with tyrosine-phosphorylated Cbl in Ph-positive leukemia. J Biol Chem 270:21468-21471
89. Kamada N, Uchino J (1978) Chronologic sequence in appearance of clinical and laboratory findings characteristic of chronic myelogenous keukemia. Blood 51:843-850
90. Kantarjian H, Smith T, O'Brien SM, Beran M, Pierce S, Talpaz M, Leukemia Service (1995) Prolonged survival in chronic myelogenous leukemia following cytogenetic response to alpha interferon therapy. Ann Int Med 122:254-261
91. Kantarjian HM, O'Brian SM, Anderlini P, Talpaz M (1996) Treatment of chronic myelogenous leukemia: current status and investigational options. Blood 87:3069-3081
92. Kantarjian HM, O'Brian SM, Keating M, Beran M, Estey E, Giralt S, Kornblau S, Rios MB, Vos D de, Talpaz M (1997) Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia 11:1617 1620
93. Kawaishi K, Kimura A, Katoh O, Sasaki A, Oguma N, Ihara A, Satow Y (1996) Decreased L-selectin expression in CD34-positive cells from patients with chronic myelocytic leukaemia. Br J Haematol 93:367-374
94. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N (1990) Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR-ABL. Proc Natl Acad Sci USA 87:6649-6653
95. Kelliher MA, Knott A, McLaughlin J, Witte ON, Rosenberg N (1991) Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR:ABL oncogene. Mol Cell Biol 11:4710-4716
96. Kelman Z, Prokocimer M, Peller S, Kahn Y, Rechavi G, Manor Y, Cohen A, Rotter V (1989) Rearrangements in the p53 gene in Philadelphia chromosome positive chronic myelogenous leukemia. Blood 74:2318-2324
97. Koch CA, Anderson D, Moran MF, Ellis C, Pawson T (1991) SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science 252:668-674
98. Kolb HJ, Mittermueller J, Clemm C, Ledderose G, Brehm G, Heim M, Wilmanns W (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462-2465
99. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, Rhee F van, Mittermueller J, Witte T de, Holler E, Ansari H (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041-2050
100. Konopka JB, Witte ON (1985) Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl eene products. Mol Cell Biol 5:3116-3123
101. Krämer A, Willer A, Hochhaus A, Saußele S, Hallek M, Hehlmann R (1997) BCR ABL stimulates adhesion of myeloid cells to fibronectin by increased expression of α5β1 integrins (abstract). J Mol Med 75:B151
102. Kurzrock R, Guttermann JV, Talpaz M (1988) The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 319:990-998
103. Lanza F, Bi S (1995) Role of p53 in leukemogenesis of chronic myeloid leukemia. Stem Cells 13:445-452
104. + cells. Blood 91:630-640
105. Lisker R, Casas I, Mutschinick O, Pérez-Chávez F, Labardini J (1980) Late appearing Philadelphia chromosome in two patients with chronic myelogenous leukemia. Blood 56:812-814
106. Lundell BI, McCarthy JB, Kovach NL, Verfaillie CM (1996) Activation-dependent α5β1 integrin-mediated adhesion to fibronectin decreases proliferation of chronic myelogenous leukemia progenitors and K562 cells. Blood 87:2450-2458
107. Marley SB, Lewis JL, Scott MA, Goldman JM, Gordon MY (1996) Evaluation of 'discordant maturation' in chronic myeloid leukaemia using cultures of primitive progenitor cells and their production of elonogenic progeny (CFU-GM). Br J Haematol 95:299-305
108. Maru Y, Witte ON (1991) The BCR gene encodes a novel serine threonine kinase activity within a single exon. Cell 67:459-468
109. Mavroudis DA, Dermíme S, Molldrem J, Jíang YZ, Raptis A, Rhee F van, Hensel N, Fellowes V, Eliopoulos G, Barrett AJ (1998) Specific depletion of alloreactive T cells in HLA-identical siblings: a method for separating graft-versus-host and graft-versus-leukaemia reactions. Br J Haematol 101:565-570
110. Melo JV (1996) The molecular biology of chronic myeloid leukemia. Leukemia 10:751-756
111. Melo JV, Gordon DE, Cross NCP, Goldman JM (1993) The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. Blood 81:158-165
112. Melo JV, Myint H, Galton DA, Goldman JM (1994) P190 BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? Leukemia 8:208-211
113. Muller AJ, Young JC, Pendergast AM, Pondel M, Landau NR, Littman DR, Witte ON (1991) BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol Cell Biol 11:1785-1792
114. + T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. Blood 91:977-983
115. Nowell PC, Hungerford DA (1960) A minute chromosome in human granulocytic leukemia. Science 132:1497-1501
116. O'Brien SG, Kirkland MA, Melo JV, Rao MH, Davidson RJ, McDonald C, Goldman JM (1994) Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines. Leukemia 8:2156-2162
117. Oda T, Tamura S, Matsuguchi T, Griffin JD, Druker BJ (1995) The SH2 domain of ABL is not required for factor-independent growth induced by BCR-ABL in a murine myeloid cell line. Leukemia 9:295-301
118. 1) by fluorescence. Nature 230:167-168
119. Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R, Meloni G, Saglio G, Salvatore F, Rotoli B (1996) Neutrophilic-chronic myelogenous leukemia (CML-N): a distinct disease with a specific marker (BCR-ABL with c3a2 junction). Blood 88:2410-2414
120. Pasternak G, Pasternak L (1994a) Behavior in vitro of long-term cultured bone marrow or blood cells from chronic myeloid leukemia: adhesion molecules and differentiation antigens as detected by immunocytochemistry. Folia Biol (Praha) 40:439-454
121. Pasternak G, Pasternak L (1994b) Persistence of bcr-abl mRNA-expressing cells in long-term cultures established from chronic myeloid leukemic bone marrow or blood. Ann Hematol 68:9-14
122. Pasternak G, Schultheis B, Heissig B, Hörner S, Sick C, Hehlmann R (1998) Does long-term culture favor normal clonogenic cells from interferon-treated patients? A concise survey on normal hematopoietic cells in chronic myelogenous leukemia. Leukemia [Suppl] (in press)
123. Pawelec G, Max H, Halder T, Bruserud Ø, Merl A, Silva P da, Kalbacher H (1996) BCR-ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. Blood 88:2118-2124
124. Pendergast AM, Traugh JA, Witte ON (1987) Normal cellular and transformation associated abl proteins share common sites for protein kinase C phosphorylation. Mol Cell Biol 7:4280 4289
125. Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, Batzer A, Rabun KM, Der CJ, Schlesinger J, Gishizky ML (1993) BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75:175-185
126. Petzer AL, Eaves CJ, Lansdorp PM, Ponchio L, Barnett MJ, Eaves AC (1996) Characterization of primitive subpopulations of normal and leukemic cells present in the blood patients with newly diagnosed as well as established chronic myeloid leukemia. Blood 88:2162-2171
127. Rhee F van, Lin F, Cullis JO, Spencer A, Cross NCP, Chase A, Garicochea B, Bungey J, Barrett J, Goldman JM (1994) Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving leukocyte transfusions before the onset of hematologic relapse. Blood 83:3377-3383
128. Roger R, Issaad C, Pallardy M, Léglise M-C, Turhan AG, Bertoglio J, Bréard J (1996) BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine-activated killer cells. Blood 87:1113-1122
129. Rowley JD (1973) A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and giemsa staining. Nature 243:290-293
130. Rowley JD (1988) Chromosome abnormalities in leukemia (Karnofsky lecture). J Clin Oncol 6:194-202
131. Rowley JD (1990) The Philadelphia chromosome translocation. A paradigm for understanding leukemia. Cancer 65:2178-2184
132. Russo C, Caroll A, Kohler S, Borowitz M, Amylon M, Homans A, Kedar A, Shuster J, Land V, Crist W, Pullen J, Link M (1991) Philadelphia chromosome and monosomy 7 in childhood acute lymphoblastic leukemia: a pediatric oncology group study. Blood 77:1050-1056
133. Salgia R, Li JL, Lo SH, Brunkhorst B, Kansas GS, Sobhany ES, Sun Y, Pisick E, Hallek M, Ernst T, Chen LB, Griffin JD (1995) Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL. J Biol Chem 270:5039-5047
134. c-Cbl. Exp Hematol 24:310-313
135. Sandberg AA (1986) The chromosomes in human leukemia. Semin Hematol 23:201-217
136. Sattler M, Salgia R (1998) Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells. Leukemia 12:637-644
137. Sawyers CL, Denny CT, Witte O (1991) Leukemia and the disruption of normal hematopoiesis. Cell 64:337-350
138. Sawyers CL, McLaughlin J, Witte ON (1995) Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med 181:307-313
139. Schlessinger J, Bar Sagi D (1994) Activation of ras and other signaling pathways by receptor tyrosine kinases. Cold Spring Harb Symp Quant Biol 59:173-179
140. Senechal K, Sawyers CL (1996) Signal transduction-based strategies for the treatment of chronic myelogenous leukemia. Mol Med Today 2:503-509
141. Shtivelman E, Lifshitz B, Gale RP, Canaani E (1986) Fused transcript of abl and bcr genes in chronic myelogenous leukemia. Nature 315:550-554
142. Shuai K, Halpern J, Hoeve J ten, Rao X, Sawyers CL (1996) Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 13:247-254
143. Sill H, Chase A, Mills KA, Apfelbeck U, Sormann S, Goldman JM, Cross NC (1994) No evidence for microsatellite instability or consistent loss of heterozygosity at selected loci in chronic myeloid leukemia blast crisis. Leukemia 8:1923-1928
144. Sill H, Goldman JM, Cross NC (1995) Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic leukemia. Blood 85:2013-2016
145. 1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc Natl Acad Sci USA 91:4504-4508
146. Skorski T, Nieborowska-Skorska M, Wlodarski P, Zon G, Iozzo RV, Calabretta B (1996) Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice. Blood 88:1005-1012
147. Smetsers TFCM, Linders EHP, Van de Locht LTF, De Witte TM, Mensink EJBM (1997) An antisense Bcr-Abl phosphodiester-tailed methylphosphonate oligonucleotide reduces the growth of chronic myeloid leukemia patient cells by a non-antisense mechanism. Br J Haematol 96:377-381
148. 1 translocation and their clinical significance. Blood 50:691-697
149. Strife A, Clarkson, B (1988) Biology of chronic myelogenous leukemia: is discordant maturation the primary defect? Semin Hematol 25:1-19
150. Strife A, Lambek C, Wisniewski D, Wachter M, Gulati SC, Clarkson B (1988) Discordant maturation as the primary biological defect in chronic myelogenous leukemia. Cancer Res 48:1035-1041
151. Sutherland HJ, Eaves CJ, Eaves AC, Dragowska W, Lansdorp PM (1989) Characterization and partial purification of human marrow cells capable of initiating long-term hematopoiesis in vitro. Blood 74:1563-1570
152. Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, Gewirtz AM, Calabretta B (1991) Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science 253:562-565
153. A in chronic myelogenous leukemia. N Engl J Med 314:1065-1069
154. Tauchi T, Boswell HS, Leibowitz D, Broxmeyer HE (1994) Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway. J Exp Med 179:167 175
155. + cells to bone marrow stroma. J Clin Invest 90:358-367
156. Tura S, for the Italian Cooperative Study Group on Chronic Myeloid Leukemia (1994) Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330:820-825
157. Uemura N, Salgia R, Li J-L, Pisick E, Sattler M, Griffin JD (1997) The BCR-ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins. Leukemia 11:376 385
158. Vaerman JL, Lammineur C, Moureau P, Lewalle P, Deldime F, Blumenfeld M, Martiat P (1995) BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but nonantisense mechanism. Blood 86:3891-3896
159. Verfaillie CM, McCarthy JB, McGlave PB (1992a) Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to basement membrane components laminin and collagen type IV. J Clin Invest 90:1232-1241
160. Verfaillie CM, Miller WJ, Boylan K, McGlave PB (1992b) Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood 79:1003-1010
161. Verfaillie CM, Bhatia R, Miller W, Mortari E, Roy V, Burger S, McCullough J, Stieglbauer K, Dewald G, Heimfeld S, Miller JS, McGlave PB (1996) BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients. Blood 87:4770-4779
162. Voncken JW, Van Schaick H, Kaartinen V, Landing B, Pattengale PK, Deemer K, Coates T, Dorseuil O, Bokoch GM, Groffen J, Heisterkamp N (1995) Increased neutrophil respiratory burst in bcr null mutants. Cell 80:719-728
163. Wada C, Shionoya S, Fujino Y, Tokuhiro H, Akahoshi T, Uchida T, Ohtani H (1994) Genomic instability of microsatellite repeats and its association with the evolution of chronic myelogenous leukemia. Blood 83:3449-3456
164. Wang JYJ (1993) Abl tyrosine kinase in signal transduction and cell cycle regulation. Curr Opin Gen Rev 3:35-43
165. Yeager AM, Kaizer H, Santos GW, Saral R, Colving OM, Stuart RK, Braine HG, Burke PJ, Ambinder RE, Burns WH (1986) Autologous bone marrow transplantation in patients with acute non-lymphocytic leukaemia using ex vivo marrow treatment with 4-hydroperoxy-cyclophosphamide. N Engl J Med 315:141-147
166. Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant J-P, Lemonnier FA, Leblond V, Langlade-Demoyen P (1998) Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 101:2290-2296
167. Zhao RCH, McIvor RS, Griffin JD, Verfaillie CM (1997) Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and non-tumorigenic in vivo. Blood 90:4687-4698